And the hits just keep on coming for the IgA nephropathy (IgAN) space, which until 2021, had no approved therapies for treating the progressive kidney disease. Five years later, there are six ...

Med-tech financings totaled $14.58 billion through August 2026, down 23% from $19.01 billion in 2025 and the lowest eight-month total after 2023’s $11.73 billion. Volume dropped to 262 deals through ...

Anaconda Biomed SL raised $56 million in a financing round for product development and clinical work, including completion of the ongoing Athena pivotal investigational device exemption study ...

Palisade Bio Inc.’s clearance from the U.S. FDA this summer to start a global phase II trial with PALI-2108 in ulcerative colitis (UC) called Ascentra UC – followed Sept. 23 by word from regulators ...

Crispr genome editing could in theory be programmed to address any gene mutation, providing cures on demand for life-threatening inherited rare diseases in newborns. The challenge is to develop a ...

Despite decades of effort, pancreatic ductal adenocarcinoma (PDAC) has remained largely resistant to immunotherapy. The emergence of KRAS inhibitors marked a long-awaited breakthrough, delivering ...

Innocare Pharma Inc. has patented non-receptor tyrosine-protein kinase TYK2 JH2 domain inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory disorders and ...

Researchers from Hanoi University of Pharmacy and collaborators pursued multitarget-directed ligands combining acetylcholinesterase (AChE) and β-site amyloid precursor protein-cleaving enzyme 1 (BACE1 ...

Axceso Biopharma Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a Bcr-Abl (Bcr-Abl1) kinase-targeting moiety ...

Pending court approval, Steri-Tech Inc., a Puerto Rico-based contract medical device sterilizer, has agreed to pay $700,000 in civil penalties as part of a settlement resolving Clean Air Act ...

Systimmune Inc. has obtained IND clearance from the FDA for SI-B037, a bispecific antibody targeting immunosuppression and other synergistic mechanisms.

Should unmodified islet cells from deceased donors be regulated as organs for transplant or as biological products? The U.S. Department of Health and Human Services (HHS) wants to know.